View this PageEdit this PageUploads to this PageHistory of this PageHomeRecent ChangesSearchHelp Guide

Issue 5 Resources

Because of the public's investments made in drug research through universities and federal agencies such as the National Institutes of Health, the profits that pharmaceutical companies earn on drugs should be regulated.

Please follow these Formatting Guidelines so that others can find the resource AND it will be easier to use these in your final position paper!

When you add a resource, also add a page for evaluations of that resource, and don't forget to take credit for the contribution, like this:

Smith, Mike. 2000. “All the Facts,” Facts and Opinion Quarterly 10: 51-68.
This is what the article says, it says lots of things and here is where I give a basic summary of its contents.

Evaluations of Smith, Mike

This site provides examples for both sides of this issue. It shows how the prices are not more expnsive in the US compared to other countries. It also shows how regulations on the prices could be risky.
contributed by StringCheese

Evaluations of 'ncpa'
This site provides information on how the USA could regulate pharmaceutical prices and how it could be helpful.
contributed by StringCheese

Evaluations of 'Impact Editorial'

Stanton, Jerry 2000. "Lesson for the United States from Foreign Price Controls on Pharmaceuticals," Conneticut Journal of International Law 16: 149-157.
This journal entry chronicles the initiatives made by other countries to regulate pharmaceutical company profits, delineating both the positive and negative aspects of the actions. It mainly addresses the use of different profit control measures.

Evaluations of Stanton, Jerry

Michaels, David and Wagner, Wendy 2004. "Equal Treatment for Regulatory Science: Extending the Controls Governing the Quality of Public Research to Private Research," American Journal of Law and Medicine 30:119-129.
This journal entry assesses the viability of the government regulating private research by the scientific misconduct regulations that currently withdraw funding from puclic research. This is important because it sets the impetus for government to be able to regulate various other aspects of private research, including profits.

Evaluations of Michaels, David

Goldberg, Robert M. 1993. "Pharmaceutical Price Controls: Saving Money Today or Lives Tomorrow?," Institute for Policy Innovation Journal 1 (found at
I will admit that because this is associated with an Institute, it may be a little skewed, however, the primary purpose of using this article is because it presents remarkable statistics about the contributions of the pharmaceutical companies to drug research and development. I also examines the impact of profit control on the status of academic and government research.

Evaluations of Goldberg, Robert M.

Levy, Richard and Menander, Kerstin 1992. Research in the Pharmaceutical Industry: Major Contributions to Biomedical Science and Implications for Public Policy, 49-58. Washington: National Pharmaceutical Council Press.
I used an excerpt from this book, which, even in 1992, suggests the possibility for federal regulation of pharmaceutical company profits, delineating both the benefits and drawbacks to intiating such a policy, as well as reason why it would be difficult for the government to justify this action.

Evaluations of Levy, Richard

Comanor, William S., 1986. The Political Economy of the Pharmaceutical Industry. Journal of Economic Literature 24: 1172-1217.
Alot of information about how economics affects the pharmaceutical industry, including indepth discussion of the controversy over monopolies within the insdustry.
Contrubuted by moto1

Evalutations of Comanor, William

Hahn, Robert W. "Policy Watch: Government Analysis of the Benefits and Costs of Regulation." 1998. The Journal of Economic Perspectives. 12: 201-210.
In depth review of the first report by the US Office of Management and Budget on the economical impact of government regulations. Discusses the issues in a broader sense, not exclusively on the pharmaceutical industry.

Evaluations of Hahn, Robert W.

LLoyd, Adam. 1994. "'Civilized' Pharmaceutical Price Regulations:
Can The U.S. Have It Too?" Regulation: The Cato Review of Business & Government.

This article discusses the Pharmaceutical Price Regulation Scheme (PPRS) which regulates the pharmaceutical industry in the United Kingdom. Through the PPRS, the British government attempts to both promote the pharmaceutical industry within their country and regulate prices. The article discusses advantages and disadvantages of this regulation from an economic standpoint and concludes that while it can possibly work in the U.K., neither a policy like the PPRS nor another price regulation scheme should be put in place in the United States.

Evaluations of Lloyd, Adam

Link to this Page